Acadia Healthcare (NASDAQ:ACHC) Issues FY 2026 Earnings Guidance

Acadia Healthcare (NASDAQ:ACHC) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 1.450-1.600 for the period, compared to the consensus EPS estimate of 1.510. The company issued revenue guidance of $3.4 billion-$3.5 billion, compared to the consensus revenue estimate of $3.4 billion.

Acadia Healthcare Price Performance

Shares of NASDAQ ACHC traded up $0.19 during trading on Tuesday, hitting $32.69. The company had a trading volume of 4,345,024 shares, compared to its average volume of 3,342,607. Acadia Healthcare has a 52 week low of $11.43 and a 52 week high of $35.83. The business’s 50-day moving average is $27.78 and its 200 day moving average is $23.36. The company has a market cap of $3.01 billion, a P/E ratio of -2.67, a PEG ratio of 11.51 and a beta of 0.64. The company has a debt-to-equity ratio of 1.27, a quick ratio of 1.71 and a current ratio of 1.71.

Acadia Healthcare (NASDAQ:ACHC) last announced its earnings results on Tuesday, July 28th. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.35 by $0.03. Acadia Healthcare had a positive return on equity of 7.09% and a negative net margin of 32.84%.The company had revenue of $865.84 million for the quarter, compared to analyst estimates of $844.19 million. Acadia Healthcare has set its FY 2026 guidance at 1.450-1.600 EPS. Equities research analysts predict that Acadia Healthcare will post 1.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ACHC has been the topic of several recent analyst reports. Cantor Fitzgerald boosted their price objective on Acadia Healthcare from $20.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, May 1st. KeyCorp raised their target price on shares of Acadia Healthcare from $30.00 to $40.00 and gave the stock an “overweight” rating in a report on Tuesday, July 14th. Barclays lifted their target price on shares of Acadia Healthcare from $20.00 to $25.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 30th. Guggenheim upped their price target on shares of Acadia Healthcare from $26.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, May 4th. Finally, UBS Group raised their price objective on shares of Acadia Healthcare from $31.00 to $39.00 and gave the stock a “buy” rating in a research note on Thursday, July 9th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $28.69.

Hedge Funds Weigh In On Acadia Healthcare

Large investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. lifted its position in shares of Acadia Healthcare by 417.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 4,728,613 shares of the company’s stock worth $67,099,000 after purchasing an additional 3,815,471 shares in the last quarter. Wellington Management Group LLP grew its position in Acadia Healthcare by 24.9% during the fourth quarter. Wellington Management Group LLP now owns 11,774,308 shares of the company’s stock valued at $167,077,000 after purchasing an additional 2,350,760 shares in the last quarter. Deerfield Management Company L.P. acquired a new position in Acadia Healthcare in the 3rd quarter valued at approximately $29,440,000. Rubric Capital Management LP purchased a new stake in Acadia Healthcare in the 3rd quarter worth approximately $27,236,000. Finally, Capitolis Liquid Global Markets LLC purchased a new stake in Acadia Healthcare in the 4th quarter worth approximately $8,954,000.

Acadia Healthcare Company Profile

Acadia Healthcare Company, Inc (NASDAQ: ACHC) is a publicly traded provider of behavioral healthcare services headquartered in Franklin, Tennessee. Founded in 2005, the company has grown through organic expansion and strategic acquisitions to establish itself as a leading specialist in mental health and addiction treatment across the United States.

Acadia operates a diversified network of inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and intensive outpatient programs.